Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RYTM 
Rhythm Pharmaceuticals Inc (RYTM)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RYTM (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 322.52% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.46B USD | Price to earnings Ratio - | 1Y Target Price 75.25 |
Price to earnings Ratio - | 1Y Target Price 75.25 | ||
Volume (30-day avg) 564925 | Beta 2.3 | 52 Weeks Range 35.17 - 68.58 | Updated Date 04/1/2025 |
52 Weeks Range 35.17 - 68.58 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.34 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -200.27% | Operating Margin (TTM) -98.63% |
Management Effectiveness
Return on Assets (TTM) -45.78% | Return on Equity (TTM) -155.91% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3176418293 | Price to Sales(TTM) 26.62 |
Enterprise Value 3176418293 | Price to Sales(TTM) 26.62 | ||
Enterprise Value to Revenue 24.41 | Enterprise Value to EBITDA -12.65 | Shares Outstanding 63223700 | Shares Floating 46960055 |
Shares Outstanding 63223700 | Shares Floating 46960055 | ||
Percent Insiders 0.54 | Percent Institutions 107.8 |
Analyst Ratings
Rating 4.45 | Target Price 73.18 | Buy 4 | Strong Buy 6 |
Buy 4 | Strong Buy 6 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Rhythm Pharmaceuticals Inc
Company Overview
History and Background
Rhythm Pharmaceuticals Inc. was founded in 2008. It is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases of obesity. Key milestones include the approval and launch of IMCIVREE (setmelanotide) for certain genetic forms of obesity.
Core Business Areas
- Rare Genetic Diseases of Obesity: Development and commercialization of therapies for patients with rare genetic diseases of obesity. Currently, focused on melanocortin-4 receptor (MC4R) pathway deficiencies.
Leadership and Structure
David Meinzinger is the Interim Chief Executive Officer. The company has a typical biopharmaceutical organizational structure with departments for R&D, commercial operations, medical affairs, and finance.
Top Products and Market Share
Key Offerings
- IMCIVREE (setmelanotide): A melanocortin-4 receptor (MC4R) agonist approved for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing and Bardet-Biedl syndrome (BBS). Competitors include off-label use of weight loss medications. Rhythm estimates the addressable population for setmelanotide is between 10,000 and 20,000 individuals globally.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the rare disease market, is characterized by high barriers to entry, orphan drug designations, and premium pricing. Obesity is a large and growing global health problem, but Rhythm focuses on specific genetic subtypes.
Positioning
Rhythm Pharmaceuticals Inc. is positioned as a leader in developing targeted therapies for rare genetic causes of obesity. Its competitive advantage lies in its focus on the MC4R pathway and its first-in-class drug, IMCIVREE.
Total Addressable Market (TAM)
The total addressable market (TAM) for rare genetic obesity is estimated to be significant, potentially reaching billions of dollars globally. Rhythm's positioning with IMCIVREE allows it to capture a significant share of this market, particularly as awareness and diagnosis of these rare conditions increase.
Upturn SWOT Analysis
Strengths
- First-in-class therapy (IMCIVREE)
- Orphan drug designation providing market exclusivity
- Strong intellectual property protection
- Experienced management team focused on rare diseases
- Focus on well defined patient population through genetic confirmation
Weaknesses
- Reliance on a single product (IMCIVREE)
- Limited commercial track record
- High research and development expenses
- Dependence on genetic testing for patient identification
- Potentially high cost of therapy affecting market access
Opportunities
- Expansion of IMCIVREE's label to include additional genetic obesity subtypes
- Development of new therapies targeting other genetic pathways involved in obesity
- Geographic expansion into new markets
- Increased awareness and diagnosis of rare genetic obesities
- Partnerships with diagnostic companies to improve patient identification
Threats
- Competition from other pharmaceutical companies developing obesity treatments
- Changes in regulatory landscape
- Pricing and reimbursement pressures from payers
- Failure to secure adequate patient access
- Clinical trial failures for pipeline candidates
Competitors and Market Share
Key Competitors
- AMGN
- NVO
- LLY
- VKTX
Competitive Landscape
Rhythm has a first-mover advantage in rare genetic obesities with its targeted MC4R agonist, IMCIVREE. However, it faces competition from companies targeting broader obesity market with drugs like Wegovy and Zepbound. Rhythm is focused on more specific targets, but the broader obesity market drugs may be used off-label.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth requires access to up-to-date financial data.
Future Projections: Future projections require real-time access to financial data and analyst estimates and are not available.
Recent Initiatives: Recent initiatives include continued commercialization efforts for IMCIVREE, clinical trials for new indications, and strategic partnerships.
Summary
Rhythm Pharmaceuticals focuses on rare genetic obesity causes and has a first-in-class drug (IMCIVREE). It faces competition from broader obesity drugs. The company's success depends on expanding its current indication and future label expansions. Its dependence on a single product, and regulatory landscape are potential threats and areas to watch out for.
Similar Companies
- AMGN
- NVO
- LLY
- VKTX
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rhythm Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2017-10-05 | Chairman, President & CEO Dr. David P. Meeker M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 283 | Website https://rhythmtx.com |
Full time employees 283 | Website https://rhythmtx.com | ||
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.